- 询价
- Nebulabio
- 中国
- NBL-293547
- 2026年01月15日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 规格：
100ug; 500ug; 1mg; Bulk
| 产品信息
品名：NebuSelect™ Recombinant Human PCBD1 Protein, 1-104aa, His-tag
中文名称：重组人PCBD1蛋白
别名：Pterin-4-alpha-carbinolamine dehydratase, PHS, 4.2.1.96, 4-alpha-hydroxy-tetrahydropterin dehydratase, Dimerization cofactor of hepatocyte nuclear factor 1-alpha, DCoH, Dimerization cofactor of HNF1, Phenylalanine hydroxylase-stimulating protein, Pterin carbinolamine dehydratase, PCD, PCBD1, DCOH, PCBD
货号：NBL-293547
品牌：Nebulabio
规格：100UG；1MG；Bulk
| 产品描述
NebuSelect™ Recombinant Human PCBD1 Protein, His-tag (Cat# NBL-293547) is expressed in E. coli with His Tag. This recombinant protein is of high purity, verified to be greater than 90% by SDS-PAGE. Endotoxin levels are less than 1 EU/µg, as determined by the LAL (Limulus Amebocyte Lysate) assay.
| 产品属性
Species:Human
Expression System:E. coli
Molecular Weight:14 kDa
Target Name:PCBD1
Purity:>90% by SDS-PAGE.
Formulation:See COA
Endotoxin:＜1 EU/ug(LAL Method)
Storage:4°C for short term. -20°C for long term.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Preparation of Recombinant Protein Spotted Arrays for Proteome‐Wide Identification of Kinase Targets
, H. 2009. Profiling the human protein‐DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 139:610‐622. Hudson, J.R., Jr., Dawson, E.P
ANTIBODY BINDING TO PROTEIN A AND PROTEIN G
of various immunoglobulines. Protein A is a 42 kDa polypeptide that binds the residues in the CH2 and CH3 domains of immunoglobulin heavy chains. Protein G is an approximatley 30 kDa polypeptide that binds immunoglobulins and albumin. Recombinant protein G
Assessing Fc Glycan Heterogeneity of Therapeutic Recombinant Monoclonal Antibodies Using NP-HPLC
Recombinant monoclonal antibodies (rMAbs) are becoming major human therapeutics to treat life-threatening diseases such as cancer. These rMAbs are produced using either in vitro cell culture processes or transgenic technology in animals
技术资料暂无技术资料 索取技术资料
